Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

R Ratzer; J Romme Christensen; B Romme Nielsen; P S Sørensen; L Börnsen; F Sellebjerg

doi:10.1016/j.jneuroim.2014.08.623

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

R Ratzer, J Romme Christensen, B Romme Nielsen, P S Sørensen, L Börnsen, F Sellebjerg

Institut for Klinisk Medicin

6 Citationer (Scopus)

Abstract

Objective: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS. Methods: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p < 0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells. Conclusion: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS.

Originalsprog	Engelsk
Tidsskrift	Journal of Neuroimmunology
Vol/bind	276
Udgave nummer	1-2
Sider (fra-til)	195-201
Antal sider	7
ISSN	0165-5728
DOI	https://doi.org/10.1016/j.jneuroim.2014.08.623
Status	Udgivet - 15 nov. 2014

Adgang til dokumentet

10.1016/j.jneuroim.2014.08.623

Citationsformater

@article{3238b1e47f794b6c85bc9923fbcb1b41,

title = "Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis",

abstract = "Objective: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS. Methods: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p < 0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells. Conclusion: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS.",

keywords = "Adult, Anti-Inflammatory Agents, Female, Flow Cytometry, Humans, Leukocytes, Mononuclear, Male, Methylprednisolone, Middle Aged, Multiple Sclerosis, Severity of Illness Index",

author = "R Ratzer and {Romme Christensen}, J and {Romme Nielsen}, B and S{\o}rensen, {P S} and L B{\"o}rnsen and F Sellebjerg",

year = "2014",

month = nov,

day = "15",

doi = "10.1016/j.jneuroim.2014.08.623",

language = "English",

volume = "276",

pages = "195--201",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

AU - Ratzer, R

AU - Romme Christensen, J

AU - Romme Nielsen, B

AU - Sørensen, P S

AU - Börnsen, L

AU - Sellebjerg, F

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Objective: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS. Methods: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p < 0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells. Conclusion: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS.

AB - Objective: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS. Methods: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p < 0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells. Conclusion: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS.

KW - Adult

KW - Anti-Inflammatory Agents

KW - Female

KW - Flow Cytometry

KW - Humans

KW - Leukocytes, Mononuclear

KW - Male

KW - Methylprednisolone

KW - Middle Aged

KW - Multiple Sclerosis

KW - Severity of Illness Index

U2 - 10.1016/j.jneuroim.2014.08.623

DO - 10.1016/j.jneuroim.2014.08.623

M3 - Journal article

C2 - 25218212

SN - 0165-5728

VL - 276

SP - 195

EP - 201

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater